Literature DB >> 6790204

Pituitary-ovarian function in normal women during the menopausal transition.

M G Metcalf, R A Donald, J H Livesey.   

Abstract

The excretion of follicle stimulating hormone (FSH), luteinizing hormone (LH), oestrogens and pregnanediol was measured in weekly urine samples collected for 14-87 weeks (median, 43 weeks) from thirty-one perimenopausal women aged 36-55 years (median, 50 years). The results were compared with those found in twenty-two postmenopausal women aged 55.4 +/- 5.4 years (mean +/- SD), and in twenty premenopausal women aged 44.4 +/- 3.4 years with regular, ovulatory, menstrual cycles. Women classed as perimenopausal had a recent history of irregular menstrual cycles following regular cyclicity. The hormone patterns observed in the perimenopausal women varied widely, both between individuals and from time to time in the same individual. They ranged from ovulatory cycles with low premenopausal levels of FSH, to transient episodes indistinguishable from those found in postmenopausal women with high levels of FSH and LH. Between these extremes were patterns rarely seen at other times in reproductive life: namely, (1) in fourteen women on thirty-two occasions lasting 2-9 weeks, postmenopausal levels of FSH and LH occurred in association with high oestrogen levels; (2) in eighteen women on thirty occasions lasting 2-8 weeks, there was an elevation of LH (but not FSH) into the postmenopausal range; (3) in thirteen women on twenty-six occasions lasting 1-2 weeks, there was an elevation of FSH (but not LH) into the postmenopausal range. These patterns were not seen in any of the premenopausal women. Typically, the approach of the menopause was marked by an increased incidence of high postmenopausal levels of FSH and LH. Ovulatory cycles were observed at all stages in the perimenopause, and occurred within 16 weeks of the last menstrual period in seven of the thirteen women who became postmenopausal during the study. It is concluded that the appearance of high levels of FSH and LH is characteristic of the perimenopause and often precedes the sustained loss of sex hormone secretion by the ageing ovary. Postmenopausal biochemical parameters are no guarantee of the postmenopausal state.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6790204     DOI: 10.1111/j.1365-2265.1981.tb00193.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  17 in total

1.  Risk factors for breast cancer with applications to selection for the prevalence screen.

Authors:  F E Alexander; M M Roberts; A Huggins
Journal:  J Epidemiol Community Health       Date:  1987-06       Impact factor: 3.710

2.  Menstrual Cycle Hormone Changes in Women Traversing Menopause: Study of Women's Health Across the Nation.

Authors:  Nanette Santoro; Sybil L Crawford; Samar R El Khoudary; Amanda A Allshouse; Sherri-Ann Burnett-Bowie; Joel Finkelstein; Carol Derby; Karen Matthews; Howard M Kravitz; Sioban D Harlow; Gail A Greendale; Ellen B Gold; Rasa Kazlauskaite; Dan McConnell; Genevieve Neal-Perry; Jelena Pavlovic; John Randolph; Gerson Weiss; Hsiang-Yu Chen; Bill Lasley
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

3.  Racial differences in menopause information and the experience of hot flashes.

Authors:  J A Grisso; E W Freeman; E Maurin; B Garcia-Espana; J A Berlin
Journal:  J Gen Intern Med       Date:  1999-02       Impact factor: 5.128

Review 4.  Reproductive hormones and the menopause transition.

Authors:  Nanette Santoro; John F Randolph
Journal:  Obstet Gynecol Clin North Am       Date:  2011-09       Impact factor: 2.844

5.  Genetic polymorphisms and obesity influence estradiol decline during the menopause.

Authors:  Maryfran R Sowers; John F Randolph; Huiyong Zheng; Mary Jannausch; Daniel McConnell; Sharon R Kardia; Carolyn J Crandall; Bin Nan
Journal:  Clin Endocrinol (Oxf)       Date:  2011-05       Impact factor: 3.478

6.  Enhanced hypothalamic-pituitary sensitivity to estrogen in premenopausal women with diminished ovarian reserve compared with older perimenopausal controls.

Authors:  Katie Zhang; Gohar Zeitlian; Goli Adel; Nanette F Santoro; Lubna Pal
Journal:  Menopause       Date:  2011-08       Impact factor: 2.953

7.  Hypoestrogenic "inactive phases" at the start of the menstrual cycle: changes with age and reproductive stage, and relationship to follicular depletion.

Authors:  Rebecca J Ferrell; Germán Rodríguez; Darryl Holman; Kathleen O'Connor; James W Wood; Maxine Weinstein
Journal:  Fertil Steril       Date:  2012-08-14       Impact factor: 7.329

8.  Factors related to declining luteal function in women during the menopausal transition.

Authors:  N Santoro; S L Crawford; W L Lasley; J L Luborsky; K A Matthews; D McConnell; J F Randolph; E B Gold; G A Greendale; S G Korenman; L Powell; M F Sowers; G Weiss
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

9.  Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.

Authors:  Adriana Valentini; Amy Finch; Jan Lubinski; Tomasz Byrski; Parviz Ghadirian; Charmaine Kim-Sing; Henry T Lynch; Peter J Ainsworth; Susan L Neuhausen; Ellen Greenblatt; Christian Singer; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

10.  Prolactin and sex steroids levels in congenital lifetime isolated GH deficiency.

Authors:  Menilson Menezes; Roberto Salvatori; Luiza D Melo; Ívina E S Rocha; Carla R P Oliveira; Rossana M C Pereira; Anita H O Souza; Eugênia H O Valença; Enaldo V Melo; Viviane C Campos; Flavia O Costa; Manuel H Aguiar-Oliveira
Journal:  Endocrine       Date:  2013-02-10       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.